Huiyu Pharmaceutical Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 1,366

Employees

  • Stock Symbol
  • 688553

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.33
  • (As of Friday Closing)

Huiyu Pharmaceutical General Information

Description

Sichuan Huiyu Pharmaceutical Co Ltd is engaged in the research and development, production and sales of anti-tumor and injection drugs.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • No. 5 Road, Chengxi Industrial Park
  • Neijiang, Sichuan 641000
  • China
+86 0832
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • No. 5 Road, Chengxi Industrial Park
  • Neijiang, Sichuan 641000
  • China
+86 0832

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Huiyu Pharmaceutical Stock Performance

As of 20-Nov-2026, Huiyu Pharmaceutical’s stock price is $1.33. Its current market cap is $831M with 626M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.33 $1.41 $1.32 - $2.54 $831M 626M 11.2M $0.04

Huiyu Pharmaceutical Financials Summary

As of 30-Sep-2026, Huiyu Pharmaceutical has a trailing 12-month revenue of $163M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 888,915 774,324 602,100 563,581
Revenue 162,797 138,799 152,517 131,038
EBITDA 1,172 (2,249) 56,515 22,218
Net Income 18,739 (3,471) 45,348 19,758
Total Assets 777,270 717,410 707,610 661,011
Total Debt 104,907 86,217 79,714 60,891
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Huiyu Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Huiyu Pharmaceutical‘s full profile, request access.

Request a free trial

Huiyu Pharmaceutical Patents

Huiyu Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026108837-A1 Salt form of pyridazine derivative, crystal form, method for preparing same, and use thereof Pending 21-Nov-2024
AU-2025214341-A1 Bispecific antibody-cytokine fusion protein and use thereof Pending 31-Jan-2024
EP-4825879-A1 Bispecific antibody-cytokine fusion protein and use thereof Pending 31-Jan-2024
WO-2025162198-A1 Bispecific antibody-cytokine fusion protein and use thereof Pending 31-Jan-2024
AU-2024351848-A1 Liposome drug delivery system and preparation method therefor, liposome formulation, use, and fat reduction drug or medical aesthetic product comprising liposome formulation Pending 27-Sep-2023 A61K31/575
To view Huiyu Pharmaceutical’s complete patent history, request access »

Huiyu Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Huiyu Pharmaceutical Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Huiyu Pharmaceutical‘s full profile, request access.

Request a free trial

Huiyu Pharmaceutical Investments (2)

Huiyu Pharmaceutical’s most recent deal was a Later Stage VC with TYK Medicines for . The deal was made on 15-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
TYK Medicines 15-Jan-2024 Later Stage VC Drug Discovery
South Pharmaceutical 25-Jan-2021 Later Stage VC Drug Discovery
To view Huiyu Pharmaceutical’s complete investments history, request access »

Huiyu Pharmaceutical ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Huiyu Pharmaceutical’s complete esg history, request access »

Huiyu Pharmaceutical Exits (1)

Huiyu Pharmaceutical’s most recent exit was on 15-Jan-2024 from TYK Medicines. The exit was categorized as with 6 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
TYK Medicines 15-Jan-2024 Completed
  • 6 buyers
To view Huiyu Pharmaceutical’s complete exits history, request access »

Huiyu Pharmaceutical FAQs

  • When was Huiyu Pharmaceutical founded?

    Huiyu Pharmaceutical was founded in 2010.

  • Where is Huiyu Pharmaceutical headquartered?

    Huiyu Pharmaceutical is headquartered in Neijiang, China.

  • What is the size of Huiyu Pharmaceutical?

    Huiyu Pharmaceutical has 1,366 total employees.

  • What industry is Huiyu Pharmaceutical in?

    Huiyu Pharmaceutical’s primary industry is Pharmaceuticals.

  • Is Huiyu Pharmaceutical a private or public company?

    Huiyu Pharmaceutical is a Public company.

  • What is Huiyu Pharmaceutical’s stock symbol?

    The ticker symbol for Huiyu Pharmaceutical is 688553.

  • What is the current stock price of Huiyu Pharmaceutical?

    As of 20-Nov-2026 the stock price of Huiyu Pharmaceutical is $1.33.

  • What is the current market cap of Huiyu Pharmaceutical?

    The current market capitalization of Huiyu Pharmaceutical is $831M.

  • What is Huiyu Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Huiyu Pharmaceutical is $163M.

  • What is Huiyu Pharmaceutical’s annual earnings per share (EPS)?

    Huiyu Pharmaceutical’s EPS for 12 months was $0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process